Pharmacokinetics, Pharmacodynamics, and Allometric Scaling of Chloroquine in a Murine Malaria Model
Brioni R. Moore,Madhu Page-Sharp,Jillian R. Stoney,Kenneth F. Ilett,Jeffrey D. Jago,Kevin T. Batty +5 more
Reads0
Chats0
TLDR
CQ showed a delayed dose-response relationship in the murine malaria model and additive efficacy when combined with DHA and the CQ-DHA combination provided an additive effect compared to each drug alone.Abstract:
Chloroquine (CQ) is an important antimalarial drug for the treatment of special patient groups and as a comparator for preclinical testing of new drugs. Pharmacokinetic data for CQ in animal models are limited; thus, we conducted a three-part investigation, comprising (i) pharmacodynamic studies of CQ and CQ plus dihydroartemisinin (DHA) in Plasmodium berghei-infected mice, (ii) pharmacokinetic studies of CQ in healthy and malaria-infected mice, and (iii) interspecies allometric scaling for CQ from 6 animal and 12 human studies. The single-dose pharmacodynamic study (10 to 50 mg CQ/kg of body weight) showed dose-related reduction in parasitemia (5- to >500-fold) and a nadir 2 days after the dose. Multiple-dose regimens (total dose, 50 mg/kg CQ) demonstrated a lower nadir and longer survival time than did the same single dose. The CQ-DHA combination provided an additive effect compared to each drug alone. The elimination half-life (t1/2), clearance (CL), and volume of distribution (V) of CQ were 46.6 h, 9.9 liters/h/kg, and 667 liters/kg, respectively, in healthy mice and 99.3 h, 7.9 liters/h/kg, and 1,122 liters/kg, respectively, in malaria-infected mice. The allometric equations for CQ in healthy mammals (CL = 3.86 × W0.56, V = 230 × W0.94, and t1/2 = 123 × W0.2) were similar to those for malaria-infected groups. CQ showed a delayed dose-response relationship in the murine malaria model and additive efficacy when combined with DHA. The biphasic pharmacokinetic profiles of CQ are similar across mammalian species, and scaling of specific parameters is plausible for preclinical investigations.read more
Citations
More filters
Journal ArticleDOI
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases
TL;DR: This review is concerned with the lysosomotropic, anti-inflammatory and immunomodulatory mechanisms of chloroquine, hydroxychloroquines, quinacrine and related analogues, and the current evidence for both their beneficial effects and potential adverse manifestations in various diseases.
Journal ArticleDOI
Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype
Degao Chen,Jing Xie,Roland Fiskesund,Wenqian Dong,Xiaoyu Liang,Jiadi Lv,Xun Jin,Jinyan Liu,Siqi Mo,Tianzhen Zhang,Feiran Cheng,Yabo Zhou,Huafeng Zhang,Ke Tang,Jingwei Ma,Yuying Liu,Bo Huang,Bo Huang +17 more
TL;DR: It is shown that chloroquine (CQ), a proven anti-malarial drug, can function as an antitumor immune modulator that switches TAMs from M2 to tumor-killing M1 phenotype by repolarizing macrophages metabolism.
Journal ArticleDOI
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
TL;DR: By overcoming drug-delivery challenges, advances can be made in the treatment of PDAC, a disease for which limited improvement in overall survival has been achieved over the past several decades.
Journal ArticleDOI
Autophagy Inhibition for Chemosensitization and Radiosensitization in Cancer: Do the Preclinical Data Support This Therapeutic Strategy?
Molly L. Bristol,Sean M. Emery,Paola Maycotte,Andrew Thorburn,Shweta Chakradeo,David A. Gewirtz +5 more
TL;DR: A careful review of the current literature suggests that caution is likely to be warranted in translating preclinical findings relating to autophagy inhibition as an adjunctive therapeutic strategy, with dramatic effects for some drugs/tumor models and modestly effects in others.
Journal ArticleDOI
A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery
Joy Wolfram,Joy Wolfram,Sara Nizzero,Sara Nizzero,Haoran Liu,Feng Li,Guodong Zhang,Zheng Li,Haifa Shen,Haifa Shen,Elvin Blanco,Mauro Ferrari,Mauro Ferrari +12 more
TL;DR: This study defines a paradigm for the combined use of macrophage-modulating agents with nanotherapeutics for improved site-specific delivery and presents a straightforward approach for addressing a major barrier in nanomedicine.
References
More filters
Journal ArticleDOI
Antimalarial drug resistance.
TL;DR: Widespread use of these drugs could roll back malaria and Artemisinin-derivative combinations are particularly effective, since they act rapidly and are well tolerated and highly effective.
Journal ArticleDOI
Chloroquine-Resistant Malaria
TL;DR: Recent field studies suggest chloroquine resistance arose in > or = 4 distinct geographic foci and substantiate an important role of immunity in the outcomes of resistant infections after chlorquine treatment.
Journal ArticleDOI
Identification of an antimalarial synthetic trioxolane drug development candidate.
Jonathan L. Vennerstrom,Sarah Arbe-Barnes,Reto Brun,Susan A. Charman,Francis C. K. Chiu,Jacques Chollet,Yuxiang Dong,Arnulf Dorn,Daniel Hunziker,Hugues Matile,Kylie Anne McIntosh,Maniyan Padmanilayam,Josefina Santo Tomas,Christian Scheurer,Bernard Scorneaux,Yuanqing Tang,Heinrich Urwyler,Sergio Wittlin,William N. Charman +18 more
TL;DR: Here it is described how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.
Journal ArticleDOI
Return of Chloroquine Antimalarial Efficacy in Malawi
Miriam K. Laufer,Phillip C. Thesing,Nicole D. Eddington,Rhoda Masonga,Fraction K. Dzinjalamala,Shannon L. Takala,Terrie E. Taylor,Christopher V. Plowe +7 more
TL;DR: Chloroquine is again an efficacious treatment for malaria, 12 years after it was withdrawn from use in Malawi.
Handbook of Animal Models of Infection
TL;DR: The Handbook will help investigators save time and effort in formulating an approach to test a new potential therapeutic agent or combination of agents for in vivo efficacy and to position the therapy for specific infections where it may have therapeutic promise.
Related Papers (5)
Artemisinin Resistance in Plasmodium falciparum Malaria
Arjen M. Dondorp,François Nosten,Poravuth Yi,Debashish Das,Aung Phae Phyo,Joel Tarning,Khin Maung Lwin,Frédéric Ariey,Warunee Hanpithakpong,Sue J. Lee,Pascal Ringwald,Kamolrat Silamut,Mallika Imwong,Kesinee Chotivanich,Pharath Lim,Trent Herdman,Sen Sam An,Shunmay Yeung,Pratap Singhasivanon,Nicholas P. J. Day,Niklas Lindegardh,Duong Socheat,Nicholas J. White +22 more
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Matthias Rottmann,Matthias Rottmann,Case W. McNamara,Bryan K. S. Yeung,Marcus C. S. Lee,Bin Zou,Bruce Russell,Bruce Russell,Patrick Seitz,Patrick Seitz,David Plouffe,Neekesh V. Dharia,Jocelyn Tan,Steven Cohen,Kathryn S. R. Spencer,Gonzalo E. González-Páez,Suresh B. Lakshminarayana,Anne Goh,Rossarin Suwanarusk,Timothy Jegla,Esther K. Schmitt,Hans-Peter Beck,Hans-Peter Beck,Reto Brun,Reto Brun,François Nosten,François Nosten,Laurent Rénia,Véronique Dartois,Thomas H. Keller,David A. Fidock,Elizabeth A. Winzeler,Elizabeth A. Winzeler,Thierry T. Diagana +33 more